A Phase 1/2 interventional study of PRF-108 and Placebo in Pain, sponsored by PainReform LTD. Completed at 1 site in Israel. Open to male participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-16.
Sponsored by PainReform LTD · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 77 studies testing ropivacaine in Pain — 3 open to participants now, 3 under way, 1 of them phase 3. Ropivacaine · Pain.
Among the 77 studies testing ropivacaine in Pain, this one is the 64th largest by enrollment, is one of 4 that started in 2010, is one of 2 in phase 1/2, and was the 10th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →3 of the 77 studies testing ropivacaine in Pain are open now, in 3 countries. Recruiting first, the newest first:
Elsan · Sites in France
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–64
University of California, Los Angeles · Sites in United States
Ages 4–12 · Healthy volunteers
By country, each count listing its studies:
Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 18 Years to 60 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
77 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 11 · Phase 4 34
First in 2001; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 60 across the 77 interventional studies. Of the 55 that completed or were terminated, 17 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 77 have an industry lead sponsor. The 10 most frequent:
PainReform LTD is the lead sponsor of 4 studies on the registry; none are open to participants now.
PainReform LTD has 1 study filed under Pain — fewer than ten, so there is no comparison to draw.
1 of the studies testing ropivacaine in Pain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03796572University of California, Los AngelesRegional Blocks for Lateral Condyle Fractures | 2027-01-07 |
Add it to your calendar (.ics) → With an account.
Among the 77 studies testing ropivacaine in Pain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a clinical study testing PRF-108 and PRF-110 (a new extended release 4% gel formulations of ropivacaine) in an experimentally induced pain model in healthy volunteers. PRF-108 and PRF-110 are designed to deliver slow release of ropivacaine over 72 hours.
This is a clinical study testing PRF-108 and PRF-110 (a new extended release 4% gel formulations of ropivacaine) in an experimentally induced pain model in healthy volunteers. PRF-108 and PRF-110 are designed to deliver slow release of ropivacaine over 72 hours.
The purpose of this study is to investigate the safety (side effects if any occurs) associated with the single administration of PRF-108 or PRF-110 and evaluate their analgesic effect in an experimentally induced pain model compared with ropivacaine Solution 0.5% and Vehicle Gel.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PRF-108 Gel, 4% ropivacaine
Drug: PRF-108
PRF-108 Gel, Vehicle
Drug: Placebo
Ropivacaine Solution 0.5%
Drug: Ropivacaine
PRF-110, 4% ropivacaine
Drug: PRF-110
Ropivacaine
PRF-108 Placebo
Solution
Also known as: ropivacaine
The duration of analgesia
Time frame: 3 days
PRF-108 and PRF-110 Safety
Time frame: 3 days
The record gives a start of Oct 2010, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ropivacaine
PainReform LTD